Amyris Biotechnologies, Emeryville, Calif.

The emerging field of synthetic biology provides candidates for a new generation of biofuels

Join Our Community of Science Lovers!

Ethanol is not the most energy-dense of fuels nor the cheapest. Consequently, Amyris Biotechnologies in Emeryville, Calif., has come up with a potentially better solution. It did so by starting with a long roster of organic compounds from which it chose potential replacements for gasoline, diesel and jet fuel that could be burned in modern engines and would be compatible with the existing petroleum infrastructure. Then the company used custom-designed microbes to produce the new fuels by fermentation from a conventional ethanol feedstock.

To create the novel strains was no small genetic feat. The task required substantial alterations to the yeast genome. Genes from the original plant source and two other organisms were inserted, and a preexisting biochemical pathway was carefully adjusted. The engineered yeast boasted a millionfold increase in yield.

A leader in the emerging field of synthetic biology, Amyris is well known for developing a strain of yeast for large-scale manufacture of a precursor to the antimalarial drug artemisinin, for which the Asian plant source is in short supply. The company, chosen in 2006 by the World Economic Forum as a Technology Pioneer, is now close to its goal of supplying cheap industrial quantities of artemisinin to developing countries.


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


Amyris decided that its expertise could prove equally profitable when applied to biofuels. It initiated a search for fuels that could be produced in the lab and that met criteria on energy content, volatility and water solubility.

The difference between engineering microbes to produce drugs versus fuel is that, ounce for ounce, drugs are much more valuable: a fuel end product has to be cheap enough to burn. Amyris will have to optimize each microbial strain so that it cranks out fuel without poisoning itself and produces enough fuel molecules so that it is economically worthwhile to grow. In the history of the large-scale chemical industry, the subtlety of technical expertise involved in this project is without precedent. Yet Amyris, which last June added several oil industry veterans to its management, has shown that it means business.

Scientific American Magazine Vol 298 Issue 1This article was published with the title “Amyris Biotechnologies, Emeryville, Calif.” in Scientific American Magazine Vol. 298 No. 1 (), p. 42
doi:10.1038/scientificamerican0108-42b

It’s Time to Stand Up for Science

If you enjoyed this article, I’d like to ask for your support. Scientific American has served as an advocate for science and industry for 180 years, and right now may be the most critical moment in that two-century history.

I’ve been a Scientific American subscriber since I was 12 years old, and it helped shape the way I look at the world. SciAm always educates and delights me, and inspires a sense of awe for our vast, beautiful universe. I hope it does that for you, too.

If you subscribe to Scientific American, you help ensure that our coverage is centered on meaningful research and discovery; that we have the resources to report on the decisions that threaten labs across the U.S.; and that we support both budding and working scientists at a time when the value of science itself too often goes unrecognized.

In return, you get essential news, captivating podcasts, brilliant infographics, can't-miss newsletters, must-watch videos, challenging games, and the science world's best writing and reporting. You can even gift someone a subscription.

There has never been a more important time for us to stand up and show why science matters. I hope you’ll support us in that mission.

Thank you,

David M. Ewalt, Editor in Chief, Scientific American

Subscribe